Intralesional dendritic cell therapy for advanced melanoma
Presented by Dr Manon Vounckx (University Hospital Brussels, Belgium)
Previous data have shown promising antitumour activity of a single intratumoral (IT) injection of autologous myeloid dendritic cells (myDC) with the synthetic saponin-based immune adjuvant AS01B and ipilimumab in combination with intravenous (IV) nivolumab. During ESMO 2024, Dr Manon Vounckx (University hospital Brussels) presented the results obtained with a treatment of IV nivolumab (10 mg q2w), IT ipilimumab (10 mg qw), IT AS01b (50 μg MPL-A/50 μg QS-21 qw) and IT autologous CD1c(BDCA-1)+/CD141(BDCA-3)+ myDC (depleting CD14+/CD19+) (1 injection) in six advanced melanoma patients who were pretreated with ICI and targeted therapy.
Two patients obtained a complete response to the treatment, while a third experienced disease stabilization. A pathological complete response was documented in 3 out of 10 injected lesions. The treatment was well-tolerated, with the most prominent adverse events consisting of transient grade 1/2 injection site reactions and constitutional symptoms.
The combination of an IT CD1c (BDCA-1)+/CD141 (BDCA-3)+ DC-injection, with weekly IT ipilimumab and AS01B, plus low-dose IV nivolumab is tolerable and demonstrated clinically meaningful anti-tumor activity in patients with refractory advanced melanoma. The presented trial will now continue as a randomized phase II study.
References:
Vounckx M, et al. ESMO 2024, #1086P.
You may also be interested in:
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
